Previous studies from our laboratory have identified that a carboxy-terminal fragment of the human growth hormone (hGH), hGH(177–191), is the lipolytic/anti-lipogenic domain of intact hGH . By targeting the key enzymes involved in lipid metabolism, hGH(177–191) is able to increase lipolysis, and decrease lipogenesis in adipose tissue, resulting in reduction of body weight gain in obese rodent models. In view of its significant clinical potential, the aim of our study is to develop the peptide into a drug for the treatment of human obesity. A series of peptide analogues of hGH(177–191) were designed, synthesized and studied for the structure-activity relationship.
- Body Weight Gain
- Human Growth Hormone
- Tibia Bone
- Peptide Analogue
- Australia Introduction
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Ng, F., Natera, S., Jiang, W.-J. US Patent No. 5,869,452 (1999).
Ng, F., Jiang, W.-J. Int. Patent Appl. PCT/AU98/00724. Published and grant pending.
Editors and Affiliations
© 2001 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Jiang, WJ., Gianello, R., Heffernan, M., Ogru, E., Libinaki, R., Ng, F. (2001). Development of a Human Growth Hormone Peptide Analogue AOD9604 into an Anti-Obesity Drug. In: Lebl, M., Houghten, R.A. (eds) Peptides: The Wave of the Future. American Peptide Symposia, vol 7. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0464-0_333
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-3905-5
Online ISBN: 978-94-010-0464-0
eBook Packages: Springer Book Archive